A new way of lung cancer treatment:immunogenic cell death
Lung cancer is one of the malignant tumors with the fastest increase in morbidity and mortality and the greatest threat to human life worldwide.Patients diagnosed with lung cancer usually receive a variety of treatments,including surgery,chemotherapy and/or radiation therapy,immunotherapy,and targeted therapy;However,the five-year survival rate for lung cancer remains low,especially when the cancer has reached an advanced stage or distant metastasis has occurred.Therefore,more effective and novel technologies must be developed to solve this problem.Inducer application of immunogenic cell death(ICD)has been proved to enhance immunity in patients receiving various types of therapy.The term ICD refers to a type of cell death that triggers an immune response to dead cell antigens,especially antigens derived from cancer cells.It was originally proposed about the effects of anti-cancer chemotherapy with traditional cytotoxic drugs.The purpose of this study is to review and discuss the role and mechanism of ICD as a promising combination immunotherapy for lung cancer.
NETL
NSTL
万方数据
